For following the competition: what moved in each program, several studies read as one move.
- povorcitinib
- axatilimab
- CDK2 Inhibitor INCB123667
- + 14 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Incyte to watchlistEvery Monday by email · turn it off any timePro · free during the beta